|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL14 |
Gene summary for RPL14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL14 | Gene ID | 9045 |
| Gene name | ribosomal protein L14 | |
| Gene Alias | CAG-ISL-7 | |
| Cytomap | 3p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P50914 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9045 | RPL14 | GSM4909282 | Human | Breast | IDC | 3.68e-76 | -4.42e-01 | -0.0288 |
| 9045 | RPL14 | GSM4909285 | Human | Breast | IDC | 2.20e-46 | -2.61e-01 | 0.21 |
| 9045 | RPL14 | GSM4909286 | Human | Breast | IDC | 3.86e-03 | -6.89e-02 | 0.1081 |
| 9045 | RPL14 | GSM4909287 | Human | Breast | IDC | 1.04e-27 | -3.06e-01 | 0.2057 |
| 9045 | RPL14 | GSM4909289 | Human | Breast | IDC | 4.06e-05 | -2.40e-01 | 0.1064 |
| 9045 | RPL14 | GSM4909290 | Human | Breast | IDC | 2.23e-04 | -1.22e-01 | 0.2096 |
| 9045 | RPL14 | GSM4909292 | Human | Breast | IDC | 1.80e-12 | -4.64e-01 | 0.1236 |
| 9045 | RPL14 | GSM4909293 | Human | Breast | IDC | 1.88e-70 | -3.78e-01 | 0.1581 |
| 9045 | RPL14 | GSM4909294 | Human | Breast | IDC | 4.58e-07 | -1.80e-01 | 0.2022 |
| 9045 | RPL14 | GSM4909295 | Human | Breast | IDC | 2.93e-15 | -3.33e-01 | 0.0898 |
| 9045 | RPL14 | GSM4909297 | Human | Breast | IDC | 1.45e-05 | -1.86e-01 | 0.1517 |
| 9045 | RPL14 | GSM4909301 | Human | Breast | IDC | 1.57e-31 | -2.72e-01 | 0.1577 |
| 9045 | RPL14 | GSM4909302 | Human | Breast | IDC | 1.74e-04 | -1.63e-01 | 0.1545 |
| 9045 | RPL14 | GSM4909306 | Human | Breast | IDC | 5.78e-30 | -2.18e-01 | 0.1564 |
| 9045 | RPL14 | GSM4909307 | Human | Breast | IDC | 1.54e-16 | -1.62e-01 | 0.1569 |
| 9045 | RPL14 | GSM4909308 | Human | Breast | IDC | 8.03e-12 | -1.24e-01 | 0.158 |
| 9045 | RPL14 | GSM4909311 | Human | Breast | IDC | 5.53e-07 | -1.70e-01 | 0.1534 |
| 9045 | RPL14 | GSM4909313 | Human | Breast | IDC | 2.31e-13 | -2.40e-01 | 0.0391 |
| 9045 | RPL14 | GSM4909315 | Human | Breast | IDC | 6.70e-12 | -2.00e-01 | 0.21 |
| 9045 | RPL14 | GSM4909316 | Human | Breast | IDC | 1.81e-04 | -2.79e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004227312 | Liver | Cirrhotic | ribosomal large subunit biogenesis | 47/4634 | 72/18723 | 4.20e-13 | 3.29e-11 | 47 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004227322 | Liver | HCC | ribosomal large subunit biogenesis | 64/7958 | 72/18723 | 2.31e-16 | 2.03e-14 | 64 |
| GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
| GO:002261332 | Liver | Cyst | ribonucleoprotein complex biogenesis | 45/496 | 463/18723 | 5.09e-14 | 2.17e-11 | 45 |
| GO:004225432 | Liver | Cyst | ribosome biogenesis | 33/496 | 299/18723 | 4.39e-12 | 1.44e-09 | 33 |
| GO:004227332 | Liver | Cyst | ribosomal large subunit biogenesis | 16/496 | 72/18723 | 4.86e-11 | 1.22e-08 | 16 |
| GO:001607221 | Liver | Cyst | rRNA metabolic process | 24/496 | 236/18723 | 1.94e-08 | 3.06e-06 | 24 |
| GO:00063643 | Liver | Cyst | rRNA processing | 23/496 | 225/18723 | 3.48e-08 | 4.80e-06 | 23 |
| GO:00344703 | Liver | Cyst | ncRNA processing | 25/496 | 395/18723 | 5.78e-05 | 3.01e-03 | 25 |
| GO:00346602 | Liver | Cyst | ncRNA metabolic process | 28/496 | 485/18723 | 1.05e-04 | 4.67e-03 | 28 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL14 | SNV | Missense_Mutation | c.524N>T | p.Ala175Val | p.A175V | P50914 | protein_coding | tolerated_low_confidence(0.06) | benign(0.087) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPL14 | SNV | Missense_Mutation | rs775806582 | c.226N>A | p.Ala76Thr | p.A76T | P50914 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RPL14 | SNV | Missense_Mutation | c.56N>A | p.Pro19His | p.P19H | P50914 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| RPL14 | SNV | Missense_Mutation | rs749693566 | c.457N>A | p.Ala153Thr | p.A153T | P50914 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-A5-A7WK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| RPL14 | SNV | Missense_Mutation | novel | c.406C>A | p.Leu136Met | p.L136M | P50914 | protein_coding | tolerated(0.12) | benign(0.111) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RPL14 | SNV | Missense_Mutation | c.563N>T | p.Ala188Val | p.A188V | P50914 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.935) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| RPL14 | SNV | Missense_Mutation | rs148088669 | c.505G>A | p.Ala169Thr | p.A169T | P50914 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RPL14 | SNV | Missense_Mutation | c.32G>T | p.Arg11Leu | p.R11L | P50914 | protein_coding | tolerated(0.05) | probably_damaging(0.971) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPL14 | insertion | In_Frame_Ins | novel | c.458_459insTGA | p.Ala153_Ala154insAsp | p.A153_A154insD | P50914 | protein_coding | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| RPL14 | insertion | Frame_Shift_Ins | novel | c.488_489insA | p.Ile166AspfsTer6 | p.I166Dfs*6 | P50914 | protein_coding | TCGA-BS-A0VI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |